Rhizen Pharmaceuticals S.A. announces preclinical presentations on RP6530, a dual PI3K delta/gamma inhibitor, for the treatment of hematological malignancies at the 55th Annual Meeting of the American Society of Hematology, 2013

La Chaux-de-Fonds, Switzerland (November 19, 2013): Rhizen Pharmaceuticals S.A. announces poster presentations for its clinical lead, RP6530, a novel, dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, in B & T-cell Lymphomas, at the Annual meeting of the American Society of Hematology (ASH) 2013 to be held from December 07-10, at New Orleans, LA.

PI3K delta and gamma isoforms are known to contribute to the development, maintenance, transformation, and proliferation of immune cells. The high level expression of these isoforms in hematopoietic cells including the T & B lymphocytes, monocytes, macrophages and neutrophils, renders dual targeting of PI3K delta and gamma an attractive approach for the treatment of lymphomas.

RP6530 is a best-in-class, highly selective, equipotent, and orally active dual PI3K delta/gamma inhibitor with impressive activity against several cell types representative of various leukemias/lymphomas. RP6530 is poised to enter clinical development in Q4 2013.

Details of the presentations:

- **Title:** “Dual PI3Kδ/γ Inhibition by RP6530 Induces Apoptosis and Cytotoxicity in B-Lymphoma Cells” (Abstract Publication Number : 4411)

- **Title:** “RP6530, a Dual PI3Kδ/γ Inhibitor, Attenuates AKT Phosphorylation and Induces Apoptosis In Primary Cutaneous T Cell Lymphoma (CTCL) Cells (Abstract Publication Number : 4418)

**Date and Time:** 09th Dec 2013, 6.00 – 8.00 pm

**Location:** Oral & Poster Abstracts Program; Session : 625, Lymphoma : Pre-clinical-Chemotherapy and Biologic agents : Poster III at the Hall G at Ernest N. Morial Convention Center, New Orleans, LA.
About Rhizen Pharmaceuticals SA:
Rhizen is a biopharmaceutical company focused on the discovery and development of novel therapeutics targeted to treat cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website (www.rhizen.com).

Contact: Anusha Gottumukkala
Email: ag@rhizen.com